Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Stony Brook tapped for CardioCell recruitment
April 2015
SHARING OPTIONS:

STONY BROOK, N.Y.—CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary, has announced that patient recruitment for its Phase 2a clinical trial for heart failure has been expanded to Stony Brook University’s Heart Institute. The study is seeking to determine if the stem cell properties of CardioCell’s ischemia-tolerant mesenchymal stem cells (itMSCs) can cause a patient’s own cardiomyocytes to improve their ability to contract, which could improve or restore heart function.
 
“The Heart Institute of Stony Brook University Medical Center is ideally suited for CardioCell’s chronic HF study,” says Dr. Sergey Sikora, CardioCell’s president and CEO. “The hospital delivers superior cardiovascular care to all of Long Island and surrounding areas, and its state-of the-art labs are staffed by experts at handling live cells like the itMSCs used in this study’s protocols.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.